BACKGROUND:Glucose and glucose degradation products (GDPs) in peritoneal dialysis fluids (PDFs) are both thought to mediate progressive peritoneal worsening. METHODS: In a multicenter, prospective, randomized crossover study, incident continuous ambulatory peritoneal dialysis patients were treated either with conventional lactate-buffered PDF (sPD regimen) or with a regimen low in glucose and GDPs: Nutrineal×1, Extraneal×1, and Physioneal×2 (NEPP regimen; all solutions: Baxter Healthcare, Utrecht, The Netherlands). After 6 months, patients were switched to the alternative regimen for another 6 months. After 6 weeks of run-in, before the switch, and at the end of the study, 4-hour peritoneal equilibration tests were performed, and overnight effluents were analyzed for cells and biomarkers. Differences between the regimens were assessed by multivariate analysis corrected for time and regimen sequence. RESULTS: The 45 patients who completed the study were equally distributed over both groups. During NEPP treatment, D(4)/D(0) glucose was lower (p < 0.01) and D/P creatinine was higher (p = 0.04). In NEPP overnight effluent, mesothelial cells (p < 0.0001), cancer antigen 125 (p < 0.0001), hyaluronan (p < 0.0001), leukocytes (p < 0.001), interleukins 6 (p = 0.001) and 8 (p = 0.0001), and vascular endothelial growth factor (VEGF, p < 0.0001) were increased by a factor of 2-3 compared with levels in sPD effluent. The NEPP regimen was associated with higher transport parameters, but that association disappeared after the addition of VEGF to the model. The association between NEPP and higher effluent levels of VEGF could not be attributed to glucose and GDP loads. CONCLUSIONS: Study results indicate preservation of the mesothelium and increased peritoneal activation during NEPP treatment. Whether the increase in VEGF reflects an increase in mesothelial cell mass or whether it points to another, undesirable mechanism cannot be determined from the present study. Longitudinal studies are needed to finally evaluate the usefulness of the NEPP regimen for further clinical use.
RCT Entities:
BACKGROUND:Glucose and glucose degradation products (GDPs) in peritoneal dialysis fluids (PDFs) are both thought to mediate progressive peritoneal worsening. METHODS: In a multicenter, prospective, randomized crossover study, incident continuous ambulatory peritoneal dialysis patients were treated either with conventional lactate-buffered PDF (sPD regimen) or with a regimen low in glucose and GDPs: Nutrineal×1, Extraneal×1, and Physioneal×2 (NEPP regimen; all solutions: Baxter Healthcare, Utrecht, The Netherlands). After 6 months, patients were switched to the alternative regimen for another 6 months. After 6 weeks of run-in, before the switch, and at the end of the study, 4-hour peritoneal equilibration tests were performed, and overnight effluents were analyzed for cells and biomarkers. Differences between the regimens were assessed by multivariate analysis corrected for time and regimen sequence. RESULTS: The 45 patients who completed the study were equally distributed over both groups. During NEPP treatment, D(4)/D(0) glucose was lower (p < 0.01) and D/P creatinine was higher (p = 0.04). In NEPP overnight effluent, mesothelial cells (p < 0.0001), cancer antigen 125 (p < 0.0001), hyaluronan (p < 0.0001), leukocytes (p < 0.001), interleukins 6 (p = 0.001) and 8 (p = 0.0001), and vascular endothelial growth factor (VEGF, p < 0.0001) were increased by a factor of 2-3 compared with levels in sPD effluent. The NEPP regimen was associated with higher transport parameters, but that association disappeared after the addition of VEGF to the model. The association between NEPP and higher effluent levels of VEGF could not be attributed to glucose and GDP loads. CONCLUSIONS: Study results indicate preservation of the mesothelium and increased peritoneal activation during NEPP treatment. Whether the increase in VEGF reflects an increase in mesothelial cell mass or whether it points to another, undesirable mechanism cannot be determined from the present study. Longitudinal studies are needed to finally evaluate the usefulness of the NEPP regimen for further clinical use.
Authors: N Posthuma; H A Verbrugh; A J Donker; W van Dorp; H A Dekker; E M Peers; P L Oe; P M ter Wee Journal: Perit Dial Int Date: 2000 Mar-Apr Impact factor: 1.756
Authors: B Rippe; O Simonsen; O Heimbürger; A Christensson; B Haraldsson; G Stelin; L Weiss; F D Nielsen; S Bro; M Friedberg; A Wieslander Journal: Kidney Int Date: 2001-01 Impact factor: 10.612
Authors: S Jones; C J Holmes; R T Krediet; R Mackenzie; D Faict; A Tranaeus; J D Williams; G A Coles; N Topley Journal: Kidney Int Date: 2001-04 Impact factor: 10.612
Authors: M A Bajo; R Selgas; M A Castro; G del Peso; C Diaz; J A Sánchez-Tomero; M Fernandez de Castro; V Alvarez; A Corbí Journal: Perit Dial Int Date: 2000 Nov-Dec Impact factor: 1.756
Authors: Janusz Witowski; Justyna Wisniewska; Katarzyna Korybalska; Thorsten O Bender; Andrzej Breborowicz; Gerhard M Gahl; Ulrich Frei; Jutta Passlick-Deetjen; Achim Jörres Journal: J Am Soc Nephrol Date: 2001-11 Impact factor: 10.121
Authors: Caatje Y le Poole; Casper G Schalkwijk; Tom Teerlink; Rob M Valentijn; Piet M Ter Wee; Frans J van Ittersum Journal: Perit Dial Int Date: 2013 Mar-Apr Impact factor: 1.756
Authors: Mark Lambie; James Chess; Kieron L Donovan; Yong Lim Kim; Jun Young Do; Hi Bahl Lee; Hyunjin Noh; Paul F Williams; Andrew J Williams; Sara Davison; Marc Dorval; Angela Summers; John D Williams; John Bankart; Simon J Davies; Nicholas Topley Journal: J Am Soc Nephrol Date: 2013-09-05 Impact factor: 10.121
Authors: Philip K T Li; Bruce F Culleton; Amaury Ariza; Jun-Young Do; David W Johnson; Mauricio Sanabria; Ty R Shockley; Ken Story; Andrey Vatazin; Mauro Verrelli; Alex W Yu; Joanne M Bargman Journal: J Am Soc Nephrol Date: 2013-08-15 Impact factor: 10.121
Authors: Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho Journal: Cochrane Database Syst Rev Date: 2018-10-26